Cargando…

Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial

This analysis of data from a Phase 3 study of adults with acute bacterial skin and skin structure infections showed that successful oral treatment with omadacycline (n = 368) or linezolid (n = 367) was associated with improvement in health-related quality of life.

Detalles Bibliográficos
Autores principales:	Chitra, Surya, Hinahara, Jordan, Goss, Thomas F, Gunter, Kyle, LaPensee, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530258/ https://www.ncbi.nlm.nih.gov/pubmed/34692889 http://dx.doi.org/10.1093/ofid/ofab459

Ejemplares similares

1356. Improvement in Quality of Life for Adults With Acute Bacterial Skin and Skin Structure Infections Following Treatment With Omadacycline or Linezolid
por: Tzanis, Evan, et al.
Publicado: (2018)

Efficacy and Safety of Omadacycline Versus Linezolid in Acute Bacterial Skin and Skin Structure Infections in Persons Who Inject Drugs
por: Moran, Gregory J., et al.
Publicado: (2022)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Correction to: Decision Analysis: Omadacycline Relative to Moxifoxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difcile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Omadacycline for Acute Bacterial Skin and Skin Structure Infections
por: Abrahamian, Fredrick M, et al.
Publicado: (2019)

Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections
por: Pai, Manjunath P, et al.
Publicado: (2021)

1688. Omadacycline in Female Adults With Cystitis: Results From a Randomized, Double-Blinded, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

1462. Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia Who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
por: Lodise, Thomas, et al.
Publicado: (2018)

Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
por: Lodise, Thomas P, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
por: Abrahamian, Fredrick M, et al.
Publicado: (2018)

An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2019)

Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
por: Leviton, Ira M., et al.
Publicado: (2022)

Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline
por: Bidell, Monique R., et al.
Publicado: (2021)

1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2018)

Analysis of a Prescription Drug Prior Authorization Program in a Medicaid Health Maintenance Organization
por: LaPensee, Kenneth
Publicado: (2003)

Hospital Admission Patterns in Adult Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and a Macrolide by Disease Severity across United States Hospitals
por: Lodise, Thomas P., et al.
Publicado: (2020)

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis
por: Karau, Melissa J., et al.
Publicado: (2022)

Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
por: Lodise, Thomas, et al.
Publicado: (2020)

700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
por: Pai, Manjunath P, et al.
Publicado: (2019)

A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin
por: Kingsley, Jeff, et al.
Publicado: (2016)

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
por: Bundrant, Lu Ann, et al.
Publicado: (2018)

734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
por: Friedrich, Lawrence, et al.
Publicado: (2019)

Palmieri’s double suture skin repair: a new double suture approach to cases of skin cancer and ulcerative lesions
por: Palmieri, Beniamino, et al.
Publicado: (2014)

Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
por: Overcash, J. Scott, et al.
Publicado: (2019)

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
por: Gotfried, Mark H., et al.
Publicado: (2017)

Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial
por: Rodriguez, George D., et al.
Publicado: (2023)

110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2019)

676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2)
por: Lodise, Thomas, et al.
Publicado: (2019)

Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection
por: Nicklas, Danielle A., et al.
Publicado: (2022)

Linezolid in the treatment of HIV-infected patients with complicated skin and soft tissue infections
por: Khachatryan, N, et al.
Publicado: (2007)

Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis
por: Lan, Shao-Huan, et al.
Publicado: (2019)

1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
por: Rodriguez, Mauricio, et al.
Publicado: (2020)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019)

Omadacycline: a novel aminomethylcycline
por: Burgos, Rodrigo M, et al.
Publicado: (2019)

Omadacycline: A Modernized Tetracycline
por: Gallagher, Jason C
Publicado: (2019)

Microbiology and Preclinical Review of Omadacycline
por: Karlowsky, James A, et al.
Publicado: (2019)

Investigating the immunomodulatory activities of omadacycline
por: Bryant, Amy E, et al.
Publicado: (2022)

Linezolid and Rifampicin Combination to Combat cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_94i6bqn01i5lgk5mtfeka86mfs